Dyslipidemia and Diabetes Reimbursement KOL Interview:
Dyslipidemia and Diabetes Reimbursement KOL Interview:
$599.00
Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin
Publisher: Biomedtracker
- Description
- Samples
Overview
This interview with a senior officer of a major insurer focuses on how payors will manage the introduction of PCSK 9 inhibitors. In the diabetes indication, the officer also comments on insulin biosimilars and touches on tiering of SGLT2/DPP4 inhibitors.
Highlights
PCSK9 Inhibitors
- Pre-authorization will require patients have tried a statin and likely ezetimibe, with differences in large versus small plans.
- Payors should be able to effectively prevent off-label use in patients without Heterozygous FH or clinical atherosclerotic cardiovascular disease (ASCVD).
- Plans will be more aggressive with prior authorization if they do not achieve good discounts in price negotiations.
- Differences in Medicare and commercial plan regulations can impact ability of pharmas to mitigate patient out-of-pocket costs.
- Payors are still figuring out how to handle the larger number of patients that could become eligible after the CV outcomes trials lead to broader labels. They will be very aggressive on statin intolerance.
Diabetes
- No special tiering for SGLT2/DPP4 FDCs. In some cases, they could end up on a preferred tier with the single drug components.
- Given steep price increases in insulin, plans are looking forward to more competition in the space.
- Currently, insulins may not be restricted as much as other products, but the introduction of biosimilars could lead to more tiering/step therapy.
SGLT2/DPP4 Inhibitor Fixed Dose Combinations
“The combination could still be in the preferred tier. If the combination is less expensive than taking the two individual
components and the net price to the plan is either at parity, where cost is the same, or it’s less expensive even, then they
might all be on the same tier.”
“…the reality is that they’re usually on multiple medications and they’re going to end up on both of these anyway. The
likelihood of the physician choosing this FDC just because it’s the same tier…they don’t even know that when they write
it, so I don’t think that would drive utilization.”
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2015 Cancer Drug Pricing Surveys 
Sign up to the